Sudeep Pharma Stock Price Today (NSE: SUDEEPPHRM)
Fundamental Score
Sudeep Pharma Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sudeep Pharma share price today is ₹957.55, down 1.70% on NSE/BSE as of 7 August 2026. Sudeep Pharma (SUDEEPPHRM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.58K (Cr). The 52-week high for SUDEEPPHRM share price is ₹990.00 and the 52-week low is ₹524.05. At a P/E ratio of 55.40x, SUDEEPPHRM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 25.17% and a debt-to-equity ratio of 0.17.
Sudeep Pharma Share Price Chart — NSE/BSE Historical Performance
Sudeep Pharma share price chart: 4.35% return over the past month. 52-week high ₹990.00, 52-week low ₹524.05.
Sudeep Pharma — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹970.05 | ₹999.95 | ₹946.35 | ₹957.55 | 2.66L (Cr) | |
| ₹973.75 | ₹990.00 | ₹952.50 | ₹974.15 | 6.22L (Cr) | |
| ₹818.40 | ₹958.95 | ₹801.40 | ₹958.95 | 16.68L (Cr) | |
| ₹869.00 | ₹890.00 | ₹860.10 | ₹871.80 | 1.31L (Cr) | |
| ₹893.50 | ₹913.95 | ₹862.35 | ₹867.60 | 5.16L (Cr) | |
| ₹861.90 | ₹909.00 | ₹856.65 | ₹881.05 | 2.83L (Cr) | |
| ₹870.00 | ₹908.00 | ₹849.00 | ₹879.15 | 3.50L (Cr) | |
| ₹864.00 | ₹891.90 | ₹859.00 | ₹861.80 | 3.26L (Cr) | |
| ₹856.40 | ₹878.80 | ₹842.00 | ₹858.10 | 4.13L (Cr) | |
| ₹874.00 | ₹888.35 | ₹858.55 | ₹869.95 | 1.08L (Cr) |
Sudeep Pharma — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹893.50 | ₹999.95 | ₹801.40 | ₹957.55 | +7.17% | |
| ₹851.95 | ₹909.00 | ₹788.35 | ₹881.05 | +3.42% | |
| ₹772.85 | ₹882.40 | ₹721.10 | ₹848.50 | +9.79% | |
| ₹710.00 | ₹742.15 | ₹624.70 | ₹742.15 | +4.53% | |
| ₹604.00 | ₹728.00 | ₹596.00 | ₹707.55 | +17.14% | |
| ₹607.40 | ₹653.55 | ₹552.05 | ₹592.55 | -2.44% | |
| ₹592.15 | ₹688.00 | ₹583.00 | ₹638.95 | +7.90% | |
| ₹602.75 | ₹645.00 | ₹524.05 | ₹609.15 | +1.06% | |
| ₹782.00 | ₹786.90 | ₹601.05 | ₹602.75 | -22.92% | |
| ₹730.00 | ₹795.00 | ₹725.00 | ₹774.15 | +6.05% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Overvalued specialty pharma play hinges on flawless execution of inorganic growth and diversification into battery materials.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Sudeep Pharma's stock experienced a rally around April 8th, mirroring a broader surge in the pharma sector. However, more recent data indicates some volatility. As of April 14, 2026, the stock was
CORE STORY (THE REAL GAME)
Sudeep Pharma is attempting a shift towards specialty, mineral-based excipients and specialty ingredients for pharma and nutrition. The market is watching if they can execute this shift while maintaining growth.
- Q3 FY26 revenue boosted by acquisition
- Expansion into battery-grade materials manufacturing
- Pharma sector rally
- Successful integration of Nutrition Supplies & Services
- Commissioning of Gujarat manufacturing facility
- Positive regulatory developments for battery materials
- Micro/SME cap - liquidity risk
- High P/E ratio relative to industry
- Execution risk in specialty shift
Promoter holding high at 76.15%, FII and DII holdings relatively stable.
Generally positive macro environment for Indian pharma, but global economic uncertainty remains a headwind.
Sudeep Advanced Materials acquired land in Gujarat for ₹20.97 crores to establish a battery-grade iron phosphate manufacturing facility.
Data unavailable.
Next 3-6 months will be critical to assess the success of the specialty shift and the progress of the battery materials venture. Watch for earnings reports and management commentary.
Primary Thesis Risk
Inability to successfully integrate acquisitions and execute specialty shift will lead to significant de-rating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sudeep Pharma Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sudeep Pharma Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUDEEPPHRM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (25.17%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.18%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (31.79%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (15.73%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (24.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (39.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (27.83x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 55.40x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-42.14% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-125.74 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Sudeep Pharma vs Pharmaceuticals Peers
Peer Comparison -
Compare Sudeep Pharma with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sudeep PharmaSudeep Pharma...Selected✓ SUDEEPPHRM • 544619 | 60.5/100 | ₹957.55₹958 | ₹9579.23₹9579.23 | 55.40Average 55.4 Average | 25.17%Excellent 25.17% Excellent | 28.18%Excellent 28.18% Excellent | 0.17Excellent 0.2 Excellent | 39.04%Excellent 39.04% Excellent | 24.45%Excellent 24.45% Excellent | 0.18% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Sudeep Pharma Quarterly Performance
Latest quarterly metrics for SUDEEPPHRM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
15.73%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
10.61%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
24.45%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
39.04%
Compounded annual net profit growth over 5 years
Sudeep Pharma Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUDEEPPHRM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sudeep Pharma Financial Statements
Annual income statement, balance sheet and cash flow for Sudeep Pharma (SUDEEPPHRM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sudeep Pharma
About SUDEEPPHRM (Sudeep Pharma)
Sudeep Pharma (SUDEEPPHRM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a curren...t market capitalisation of ₹9.58K (Cr). Sudeep Pharma has delivered a Return on Equity (ROE) of 25.17% and a ROCE of 28.18%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking SUDEEPPHRM share price can monitor key metrics including P/E ratio, promoter holding of 76.15%, and quarterly earnings growth.
Company Details
SUDEEPPHRM Share Price: Frequently Asked Questions
What is the current share price of Sudeep Pharma?
Sudeep Pharma (SUDEEPPHRM) trades at ₹957.55 on NSE and BSE. Market cap ₹9.58K (Cr). Educational data only.
What is the P/E ratio of Sudeep Pharma?
Sudeep Pharma has a P/E of 55.40x vs industry average 34.89x.
What is the Bull Run score for Sudeep Pharma?
Sudeep Pharma has a Bull Run score of 60.5/100 based on 25+ financial parameters.
Does Sudeep Pharma pay dividends?
Sudeep Pharma has a dividend yield of 0.18%. Past dividends don't guarantee future payments.
What is the ROE of Sudeep Pharma?
Sudeep Pharma has ROE of 25.17%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sudeep Pharma?
Sudeep Pharma has debt-to-equity of 0.17.
Is Sudeep Pharma a good investment?
Bull Run gives Sudeep Pharma a score of 60.5/100. This is not investment advice — consult a SEBI-registered advisor.